Hubers, A J
Heideman, D A M
Burgers, S A
Herder, G J M
Sterk, P J
Rhodius, R J
Smit, H J
Krouwels, F
Welling, A
Witte, B I
Duin, S
Koning, R
Comans, E F I
Steenbergen, R D M
Postmus, P E
Meijer, G A
Snijders, P J F
Smit, E F
Thunnissen, E
Article History
Received: 30 June 2014
Revised: 6 October 2014
Accepted: 1 December 2014
First Online: 26 February 2015
Competing interests
: Pieter E. Postmus has board membership at Boehringer Ingelheim (advisory board on nintedanib), payment for lectures BMS (chair and lecture at symposium at WCLC 2013). The remaining authors declare no conflict of interest.